EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Progression of NUS1 ‐Associated Parkinson's Disease and the Diagnostic Potential of Plasma NgBR

Lizhi Li, Juanjuan Huang, Yaqin Xiang, Xuxiang Zhang iD, Qian Xu iD, Qiying Sun iD, Zhenhua Liu, Xinxiang Yan, Jinchen Li iD, Beisha Tang, Jifeng Guo iD

CNS Neuroscience & Therapeutics · 2025

DOI: 10.1111/cns.70549 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CNS Neuroscience & Therapeutics, 2025. Verfasst von Lizhi Li und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, China. Hauptthemen laut MEDLINE: Parkinson Disease, Disease Progression, Receptors, Cell Surface. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Technology Major Project of Hunan Provincial Science and Technology Department, National Key Research and Development Program of China, the National Key Plan for Scientific Research and Development of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

The study aimed to investigate the role of NUS1 variants in Parkinson's disease (PD) progression and evaluate plasma Nogo‐B receptor (NgBR) as a potential biomarker.

Methods

We recruited 228 PD patients, including 38 with NUS1 variants ( NUS1 ‐PD) and 190 without (GU‐PD), and all underwent at least two follow‐up visits. Linear mixed‐effects models assessed motor and non‐motor symptom progression. Plasma NgBR levels were measured in PD, Multiple System Atrophy (MSA), Progressive Supranuclear Palsy (PSP), and healthy controls (HC), and receiver operating characteristic curve analysis evaluated its diagnostic efficacy.

Results

NUS1 ‐PD demonstrated an earlier age at onset and more severe motor features than GU‐PD at baseline. Longitudinal analyses showed similar progression rates of UPDRS III and H&Y stage (off‐medication) in NUS1 ‐PD and GU‐PD, but a slower progression rate of urinary function in NUS1 ‐PD ( p = 0.024). Plasma NgBR levels were higher in PD than in HC, MSA, and PSP, with AUC values of 0.6832, 0.6716, and 0.6628, respectively. Plasma NgBR was associated with UPDRS III ( p = 0.006) and cognitive impairment ( p = 0.010).

Conclusion

NUS1 variants show no impact on PD progression, while plasma NgBR may serve as a potential biomarker for PD diagnosis and clinical characteristics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Parkinson DiseaseDisease ProgressionReceptors, Cell SurfaceHumansMaleFemaleAgedMiddle AgedBiomarkersMultiple System AtrophyLongitudinal StudiesSupranuclear Palsy, Progressive

Stichwörter der Autor:innen

NUS1 geneNogo‐B receptorParkinson's diseasedisease progression

Substanzen

NUS1 protein, humanReceptors, Cell SurfaceBiomarkers

Autor:innen und Institutionen

  • Department of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
  • Department of Radiology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
  • Department of Geriatrics, Xiangya Hospital, Central South University, Changsha, Hunan, China.
  • National Clinical Research Centre for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China.
  • Key Laboratory of Hunan Province in Neurodegenerative Disorders, Central South University, Changsha, Hunan, China.
  • Hunan Key Laboratory of Medical Genetics, School of Life Sciences, Centre for Medical Genetics, Central South University, Changsha, China.

ORCID-Profile: Xuxiang Zhang, Qian Xu, Qiying Sun, Jinchen Li, Jifeng Guo

Förderung

  • the Technology Major Project of Hunan Provincial Science and Technology Department
  • National Key Research and Development Program of China
  • the National Key Plan for Scientific Research and Development of China

Zitieren

APA

Li, L., Huang, J., Xiang, Y., Zhang, X., Xu, Q., Sun, Q., Liu, Z., Yan, X., Li, J., Tang, B., & Guo, J. (2025). The Progression of NUS1 ‐Associated Parkinson's Disease and the Diagnostic Potential of Plasma NgBR. CNS Neuroscience & Therapeutics. https://doi.org/10.1111/cns.70549

Vancouver

Li L, Huang J, Xiang Y, Zhang X, Xu Q, Sun Q, et al. The Progression of NUS1 ‐Associated Parkinson's Disease and the Diagnostic Potential of Plasma NgBR. CNS Neuroscience & Therapeutics. 2025. doi:10.1111/cns.70549

BibTeX
@article{Li2025,
  author = {Li, Lizhi and Huang, Juanjuan and Xiang, Yaqin and Zhang, Xuxiang and Xu, Qian and Sun, Qiying and Liu, Zhenhua and Yan, Xinxiang and Li, Jinchen and Tang, Beisha and Guo, Jifeng},
  title = {The Progression of NUS1 ‐Associated Parkinson's Disease and the Diagnostic Potential of Plasma NgBR},
  journal = {CNS Neuroscience & Therapeutics},
  year = {2025},
  doi = {10.1111/cns.70549}
}
Kostenlos starten →